SecBot SecBot
SECBOTREPLAY Home › Report › AZN

AZN · AstraZeneca announced positive interim results from the Phase III I CAN…

ASTRAZENECA PLC · 6-K filed Apr 21, 2026 at 06:19 ET

At the news

BULLISHIMPACT 8/10

6-K filed Apr 21, 2026 at 06:19 ET

AstraZeneca announced positive interim results from the Phase III I CAN trial, showing that Ultomiris (ravulizumab) met its primary endpoint with a statistically significant and clinically meaningful reduction in proteinuria in adults with immunoglobulin A nephropathy (IgAN). The company plans to seek accelerated approval in key markets and present full results at a future medical meeting.

  • Ultomiris met the primary endpoint of statistically significant and clinically meaningful reduction in proteinuria (measured by 24-hour UPCR) at week 34 in the I CAN Phase III trial.
  • The trial enrolled approximately 510 adults with IgAN at risk of disease progression across 28 countries.
  • Ultomiris demonstrated rapid reduction in proteinuria as early as week 10.
  • The safety profile was consistent with known data, with no new safety concerns.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access